# Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study
Canonical URL: https://biopharmsignal.com/news/INTS/intensity-therapeutics-inc-provides-update-on-the-phase-2-presurgical-triple-negative-breast-cancer-invincible-4-study
Ticker: INTS
Company: Intensity Therapeutics
Source: Intensity Therapeutics
Published: 2026-03-12 11:30 EST
Original Source URL: https://ir.intensitytherapeutics.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-15 11:45 EST — [Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)](https://biopharmsignal.com/news/INTS/intensity-therapeutics-inc-restarts-patient-treatment-in-the-randomized-presurgi-51761e30) — Source: Intensity Therapeutics
- 2026-07-01 12:00 EST — [Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6](https://biopharmsignal.com/news/INTS/intensity-therapeutics-provides-mid-year-update-highlighting-late-stage-developm-93ef635a) — Source: Intensity Therapeutics
- 2026-05-14 12:00 EST — [Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award](https://biopharmsignal.com/news/INTS/intensity-therapeutics-recognized-with-ghp-magazine-s-2026-healthcare-and-pharmaceutical-award) — Source: Intensity Therapeutics
- 2026-05-07 20:06 EST — [Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/INTS/intensity-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Intensity Therapeutics
- 2026-04-15 13:15 EST — [Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation](https://biopharmsignal.com/news/INTS/intensity-therapeutics-recognized-with-pinnacle-award-for-excellence-in-healthcare-innovation) — Source: Intensity Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)